These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24776976)

  • 1. Prostate cancer: enzalutamide impresses in European studies.
    Payton S
    Nat Rev Urol; 2014 May; 11(5):243. PubMed ID: 24776976
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-androgen monotherapy for metastatic prostate cancer.
    Attard G
    Lancet Oncol; 2014 May; 15(6):543-4. PubMed ID: 24739898
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: enzalutamide PREVAILs.
    Payton S
    Nat Rev Urol; 2014 Jul; 11(7):361. PubMed ID: 24934449
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Tombal B
    N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111
    [No Abstract]   [Full Text] [Related]  

  • 6. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy.
    Althaus A; Kibel A
    Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395
    [No Abstract]   [Full Text] [Related]  

  • 7. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy.
    Chow K; Murphy DG
    Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073
    [No Abstract]   [Full Text] [Related]  

  • 8. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
    Tombal B; Borre M; Rathenborg P; Werbrouck P; Van Poppel H; Heidenreich A; Iversen P; Braeckman J; Heracek J; Baskin-Bey E; Ouatas T; Perabo F; Phung D; Hirmand M; Smith MR
    Lancet Oncol; 2014 May; 15(6):592-600. PubMed ID: 24739897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
    Trump D
    Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Cicero G; DE Luca R; Dorangricchia P; Dieli F
    Anticancer Res; 2017 Mar; 37(3):1475-1480. PubMed ID: 28314320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Asian J Androl; 2014; 16(6):803-4. PubMed ID: 25080931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all.
    Maughan BL; Antonarakis ES
    Asian J Androl; 2014; 16(6):807-8. PubMed ID: 25155108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.
    Nhean S; Bravo J; Sheehan NL; Walmsley S; Tilley D; Tseng AL
    AIDS; 2018 Nov; 32(17):2640-2642. PubMed ID: 30379691
    [No Abstract]   [Full Text] [Related]  

  • 15. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.
    Menon MP; Higano CS
    Curr Oncol Rep; 2013 Apr; 15(2):69-75. PubMed ID: 23341368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.